BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 18471707)

  • 1. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
    Katz MH; Pisters PW; Evans DB; Sun CC; Lee JE; Fleming JB; Vauthey JN; Abdalla EK; Crane CH; Wolff RA; Varadhachary GR; Hwang RF
    J Am Coll Surg; 2008 May; 206(5):833-46; discussion 846-8. PubMed ID: 18471707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of borderline resectable pancreatic cancer.
    Cooper AB; Tzeng CW; Katz MH
    Curr Treat Options Oncol; 2013 Sep; 14(3):293-310. PubMed ID: 23793524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
    Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
    Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
    Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
    Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.
    Kang CM; Chung YE; Park JY; Sung JS; Hwang HK; Choi HJ; Kim H; Song SY; Lee WJ
    J Gastrointest Surg; 2012 Mar; 16(3):509-17. PubMed ID: 22183861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?
    Kelly KN; Macedo FI; Merchant NB
    Adv Surg; 2020 Sep; 54():49-68. PubMed ID: 32713439
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.
    McClaine RJ; Lowy AM; Sussman JJ; Schmulewitz N; Grisell DL; Ahmad SA
    HPB (Oxford); 2010 Feb; 12(1):73-9. PubMed ID: 20495649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
    Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
    Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining venous involvement in borderline resectable pancreatic cancer.
    Chun YS; Milestone BN; Watson JC; Cohen SJ; Burtness B; Engstrom PF; Haluszka O; Tokar JL; Hall MJ; Denlinger CS; Astsaturov I; Hoffman JP
    Ann Surg Oncol; 2010 Nov; 17(11):2832-8. PubMed ID: 20725860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodality management of borderline resectable pancreatic adenocarcinoma.
    Prakash LR; Katz MHG
    Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of group B borderline resectable pancreatic cancer: retrospective analysis.
    Oh TG; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Seong J; Kang CM; Lee WJ; Park JY
    Gut Liver; 2014 Sep; 8(5):557-62. PubMed ID: 25228978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in the management of borderline resectable pancreatic cancer.
    Sharma J; Ng J; Goodman MD; Saif MW
    JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
    Peng JS; Wey J; Chalikonda S; Allende DS; Walsh RM; Morris-Stiff G
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):373-378. PubMed ID: 31176601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.